The startup has developed the first oncology precision medicine system that selects “personalized treatment for each patient.”
As explained by the company itself, OPS (Oncology Precision System) is an Artificial Intelligence solution that determines the best combination of therapies against breast and lung cancer through an automatic learning system. This tool makes it easier for oncologists to select the most appropriate treatment for each patient, taking into account their individual genetic characteristics.
The company ensures that KeyZell OPS, with 89% efficiency , “is the only precision medicine system for oncology use focused on treatment and patient care. In addition, it identifies patterns and makes predictions contemplating up to 112 biomarkers , helping in predicting the best personalized treatment that guarantees the highest 5-year survival rate”.
For its selection, the tool takes into account variables such as clinical analysis data, the molecular DNA profile of the patient, the IHC (immuno-histochemical) profile, effectiveness, toxicity, etc.
The same treatment is frequently applied to patients with the same type of cancer, however, there are groups of patients that respond in markedly different ways . For this reason, the startup intends to continue developing this pioneering system worldwide and lead the biomedical revolution of precision medicine with KeyZell OPS.
Iván Románico , head of oncology at Hospital Ángeles Puebla , stated that “we are witnessing the future of precision medicine with great enthusiasm and responsibility. Thanks to this type of tool, oncologists offer patients a more effective solution tailored to their individual characteristics that undoubtedly have an impact on their quality of life”.
“We want KeyZell OPS to be the benchmark personalized treatment service against cancer in the field of precision medicine. With this tool, our goal is to reverse the mortality figures for this disease and make them more and more year after year.” hopeful,” says José de Corral, CEO of KeyZell.